OLMA
Olema Pharmaceuticals, Inc.
$13.85
-0.75%
$1.2B
No data for this timeframe.
Vol
Market Cap$1.2B
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (89%)
Inst. Holders8 funds
Inst. Value$260.0M
Inst. Activity3 buys / 3 sells
SEC Reports3
Press Releases3
Recent Activity
May 19, 2026
other
Olema Oncology to Participate in Upcoming Investor Conferences
Olema Oncology to Participate in Upcoming Investor Conferences
May 12, 2026
SEC
Olema Pharmaceuticals reported Q1 2026 financial results, with a net loss of $53.1M (vs $30.4M in Q1 2025) driven by inc
8-K — Impact 4/10
May 12, 2026
SEC
Olema Oncology reported Q1 2026 EPS of -$0.52, a 7.2% beat vs consensus of -$0.54, but net loss widened to $53.1M from $
PRESS-RELEASE — Impact 5/10
Apr 29, 2026
SEC
Olema Pharmaceuticals filed DEFA14A additional definitive proxy solicitation materials. The only substantive recent even
DEFA14A — Impact 2/10
Apr 28, 2026
Insider
Raman Prakash sold 2,911 shares
Director @ $0.00 ($0.00)
Mar 4, 2026
Insider
Mitchell Shawnte sold 25,000 shares
CHIEF LEGAL OFFICER @ $4.37 ($109.3K)
Mar 4, 2026
Insider
Mitchell Shawnte sold 25,000 shares
CHIEF LEGAL OFFICER @ $0.00 ($0.00)
Inst.
FMR LLC — DOUBLED
5,023,092 shares ($125.6M)
Price Targets
$41.82
+201.8% upside
Strong Buy
Current $13.86
Low $23.00
Median $40.00
High $62.00
11 analysts
$23.00
$62.00
Analyst Ratings
7Strong Buy
10Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 13, 2026 | Guggenheim | MAINTAIN | Buy → Buy |
| Mar 27, 2026 | Wolfe Research | INITIATE | Peer Perform |
| Mar 18, 2026 | JP Morgan | MAINTAIN | Overweight → Overweight |
| Mar 18, 2026 | Goldman Sachs | MAINTAIN | Buy → Buy |
| Mar 17, 2026 | Citigroup | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.56 | $-0.63 — $-0.49 | -10% YoY | 10 |
| Next Q | $-0.57 ▲ +1.1% | $-0.69 — $-0.47 | -16% YoY | 10 |
| Current FY | $-2.24 ▲ +2.0% | $-2.62 — $-1.94 | -20% YoY | 10 |
| Next FY | $-2.33 ▲ +8.6% | $-3.04 — $-0.92 | -4% YoY | 10 |
Latest Reports
NEUTRAL
8-K
4/10
Olema Pharmaceuticals reported Q1 2026 financial results, with a net loss of $53.1M (vs $30.4M in Q1 2025) driven by inc
May 12, 2026
NEUTRAL
PRESS-RELEASE
5/10
Olema Oncology reported Q1 2026 EPS of -$0.52, a 7.2% beat vs consensus of -$0.54, but net loss widened to $53.1M from $
May 12, 2026
NEUTRAL
Press
4/10
Olema Oncology announced upcoming presentations of initial Phase 1 data for OP-3136 and a trial-in-progress overview of
Apr 21, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| FMR LLC | $125.6M | DOUBLED |
| VANGUARD GROUP INC | $89.0M | — |
| MORGAN STANLEY | $16.6M | TRIM |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $10.2M | NEW |
| TWO SIGMA INVESTMENTS, LP | $9.8M | DOUBLED |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Apr 28, 2026 | Raman Prakash | A | $0.00 |
| Mar 4, 2026 | Mitchell Shawnte | M | $109.3K |
| Mar 4, 2026 | Mitchell Shawnte | M | $0.00 |
| Mar 3, 2026 | Mitchell Shawnte | M | $65.5K |
| Mar 3, 2026 | Mitchell Shawnte | M | $0.00 |
8 institutional holders with $260.0M total value (10,399,160 shares) as of 2025-Q4. Top holders: FMR, VANGUARD, MORGAN.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | FMR LLC | 5,023,092 | $125.6M | 48.3% | DOUBLED +16972.6% |
| 2 | VANGUARD GROUP INC | 3,561,355 | $89.0M | 34.2% | — |
| 3 | MORGAN STANLEY | 665,803 | $16.6M | 6.4% | TRIM -57.2% |
| 4 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 407,141 | $10.2M | 3.9% | NEW |
| 5 | TWO SIGMA INVESTMENTS, LP | 393,658 | $9.8M | 3.8% | DOUBLED +259.4% |
| 6 | BANK OF AMERICA CORP /DE/ | 238,914 | $6.0M | 2.3% | TRIM -70.2% |
| 7 | WELLS FARGO & COMPANY/MN | 84,130 | $2.1M | 0.8% | ADD +84.2% |
| 8 | RENAISSANCE TECHNOLOGIES LLC | 25,067 | $626.7K | 0.2% | TRIM -72.2% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| FMR LLC | DOUBLED | 29,422 | 5,023,092 | +16972.6% | $125.6M | 2025-Q4 |
| MORGAN STANLEY | TRIM | 1,555,887 | 665,803 | -57.2% | $16.6M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 109,526 | 393,658 | +259.4% | $9.8M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | TRIM | 802,304 | 238,914 | -70.2% | $6.0M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 45,661 | 84,130 | +84.2% | $2.1M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 90,100 | 25,067 | -72.2% | $626.7K | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 58,800 | 90,100 | +53.2% | $882.1K | 2025-Q3 |
| MORGAN STANLEY | DOUBLED | 451,691 | 1,437,407 | +218.2% | $6.1M | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | ADD | 62,926 | 92,501 | +47.0% | $394.1K | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | ADD | 23,239 | 38,215 | +64.4% | $162.8K | 2025-Q2 |
| FMR LLC | DOUBLED | 1,815 | 28,241 | +1456.0% | $120.3K | 2025-Q2 |
| UBS Group AG | DOUBLED | 560,506 | 1,151,147 | +105.4% | $4.3M | 2025-Q1 |
| MORGAN STANLEY | TRIM | 1,024,477 | 451,691 | -55.9% | $1.7M | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 157,300 | 64,600 | -58.9% | $242.9K | 2025-Q1 |
| FMR LLC | NEAR_EXIT | 45,828 | 1,815 | -96.0% | $6.8K | 2025-Q1 |
| CITADEL ADVISORS LLC | ADD | 1,265,745 | 1,706,007 | +34.8% | $9.9M | 2024-Q4 |
| MORGAN STANLEY | DOUBLED | 249,601 | 1,024,477 | +310.4% | $6.0M | 2024-Q4 |
| UBS Group AG | DOUBLED | 77,547 | 560,506 | +622.8% | $3.3M | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 29,400 | 157,300 | +435.0% | $917.1K | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 16,767 | 22,725 | +35.5% | $132.5K | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 330,761 | — | $3.9M | 2024-Q3 |
| MORGAN STANLEY | TRIM | 335,571 | 249,601 | -25.6% | $3.0M | 2024-Q3 |
6 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Apr 28, 2026 | Raman Prakash | Director | A | 2,911 | $0.00 | $0.00 |
| Mar 4, 2026 | Mitchell Shawnte | CHIEF LEGAL OFFICER | M | 25,000 | $4.37 | $109.3K |
| Mar 4, 2026 | Mitchell Shawnte | CHIEF LEGAL OFFICER | M | 25,000 | $0.00 | $0.00 |
| Mar 3, 2026 | Mitchell Shawnte | CHIEF LEGAL OFFICER | M | 15,000 | $4.37 | $65.5K |
| Mar 3, 2026 | Mitchell Shawnte | CHIEF LEGAL OFFICER | M | 15,000 | $0.00 | $0.00 |
| Feb 2, 2026 | Austin Sasha Lu | VP of Finance and Controller | A | 11,700 | $0.00 | $0.00 |
| Feb 2, 2026 | Austin Sasha Lu | VP of Finance and Controller | A | 29,250 | $0.00 | $0.00 |
| Feb 2, 2026 | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | A | 250,000 | $0.00 | $0.00 |
| Feb 2, 2026 | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | A | 106,250 | $0.00 | $0.00 |
| Feb 2, 2026 | Mitchell Shawnte | CHIEF LEGAL OFFICER | A | 220,000 | $0.00 | $0.00 |
| Feb 2, 2026 | Mitchell Shawnte | CHIEF LEGAL OFFICER | A | 56,250 | $0.00 | $0.00 |
| Feb 2, 2026 | Bohen Sean | PRESIDENT AND CEO | A | 850,000 | $0.00 | $0.00 |
| Feb 2, 2026 | Bohen Sean | PRESIDENT AND CEO | A | 275,000 | $0.00 | $0.00 |
| Feb 2, 2026 | Zojwalla Naseem | CHIEF MEDICAL OFFICER | A | 250,000 | $0.00 | $0.00 |
| Feb 2, 2026 | Zojwalla Naseem | CHIEF MEDICAL OFFICER | A | 106,250 | $0.00 | $0.00 |
3 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 3 neutral. Avg impact: 3.7/10.
NEUTRAL
8-K
4/10
Olema Pharmaceuticals reported Q1 2026 financial results, with a net loss of $53.1M (vs $30.4M in Q1
May 12, 2026
NEUTRAL
PRESS-RELEASE
5/10
Olema Oncology reported Q1 2026 EPS of -$0.52, a 7.2% beat vs consensus of -$0.54, but net loss wide
May 12, 2026
NEUTRAL
DEFA14A
2/10
Olema Pharmaceuticals filed DEFA14A additional definitive proxy solicitation materials. The only sub
Apr 29, 2026
NEUTRAL
4/10
Olema Oncology announced upcoming presentations of initial Phase 1 data for OP-3136 and a trial-in-p
Apr 21, 2026
MIXED
5/10
Olema Oncology released preclinical data showing palazestrant fully recruits the NCoR1 corepressor f
Apr 17, 2026
NEUTRAL
5/10
Olema Oncology reported financial results for 2025, showing increased net losses due to higher R&D s
Mar 16, 2026
Current analyst consensus: Strong Buy (89% buy). Based on 19 analysts: 7 strong buy, 10 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$41.82 mean target
+201.8% upside
Strong Buy (1.31)
$23.00 Low
$62.00 High
| Metric | Value |
|---|---|
| Current Price | $13.86 |
| Target Low | $23.00 |
| Target Mean | $41.82 |
| Target Median | $40.00 |
| Target High | $62.00 |
| # Analysts | 11 |
| Recommendation | Strong Buy (1.31) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.56 | $-0.63 | $-0.49 | -10.3% | +0.3% | 3↑ 2↓ | $0.0B | 0.0% | 10 |
| Next Q 2026-09-30 |
$-0.57 | $-0.69 | $-0.47 | -16.0% | +1.1% | 3↑ 2↓ | $0.0B | 0.0% | 10 |
| Current FY 2026-12-31 |
$-2.24 | $-2.62 | $-1.94 | -19.9% | +2.0% | 3↑ 3↓ | $0.0B | 0.0% | 10 |
| Next FY 2027-12-31 |
$-2.33 | $-3.04 | $-0.92 | -3.8% | +8.6% | 3↑ 3↓ | $0.0B | 1388.0% | 10 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.562 | |
| 7d ago | $0.000 | -0.562 |
| 30d ago | $-0.564 | +0.002 |
| 60d ago | $-0.565 | +0.002 |
| 90d ago | $-0.564 | +0.001 |
10 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 4 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 13, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
| Mar 27, 2026 | Wolfe Research | INITIATE | — | Peer Perform |
| Mar 18, 2026 | JP Morgan | MAINTAIN | Overweight | Overweight |
| Mar 18, 2026 | Goldman Sachs | MAINTAIN | Buy | Buy |
| Mar 17, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| Mar 17, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
| Mar 9, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Feb 11, 2026 | Stifel | INITIATE | — | Buy |
| Jan 7, 2026 | UBS | INITIATE | — | Buy |
| Jan 7, 2026 | Piper Sandler | INITIATE | — | Overweight |
| Dec 12, 2025 | Citigroup | MAINTAIN | Buy | Buy |
| Dec 11, 2025 | Oppenheimer | MAINTAIN | Outperform | Outperform |
| Dec 11, 2025 | Goldman Sachs | MAINTAIN | Buy | Buy |
| Dec 11, 2025 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 7 | 10 | 2 | 0 | 0 | 89% | |
| Apr 1, 2026 | 7 | 10 | 2 | 0 | 0 | 89% | |
| Mar 1, 2026 | 7 | 10 | 1 | 0 | 0 | 94% | |
| Feb 1, 2026 | 6 | 10 | 1 | 0 | 0 | 94% | |
| Jan 1, 2026 | 6 | 8 | 1 | 0 | 0 | 93% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 19, 2026
other
Olema Oncology to Participate in Upcoming Investor Conferences
Olema Oncology to Participate in Upcoming Investor Conferences
May 18, 2026
short_volume
Short Volume: OLMA — 57.9% short (0.5M / 0.9M)
Short: 495,051 | Exempt: 0 | TRF Vol: 855,258 | Short Ratio: 57.9% | Off-exchange volume (dark pool + OTC)
May 12, 2026
earnings
Olema Oncology Reports First Quarter 2026 Financial and Operating Results
<p>SAN FRANCISCO, May 12, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=RANK8KL15ZMBD2kMt9H_RON8BUpoMqr9uoHYfoRypZlvd
May 12, 2026
Clinical Trial
A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer
Phase Phase 2 — COMPLETED
May 12, 2026
earnings_calendar
OLMA Q1 2026 Earnings Scheduled — 2026-05-12
May 11, 2026
earnings_calendar
OLMA Q1 2026 Earnings Scheduled — 2026-05-11
May 4, 2026
other
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apr 21, 2026
fda
Olema Oncology to Present Initial Clinical Data for OP-3136 at the 2026 ASCO Annual Meeting
Olema Oncology to Present Initial Clinical Data for OP-3136 at the 2026 ASCO Annual Meeting
Apr 17, 2026
fda
Olema Oncology Announces Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting
Olema Oncology Announces Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting
Apr 2, 2026
other
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 24, 2026
short_volume
Short Volume: OLMA — 70.2% short (0.4M / 0.5M)
Short: 367,400 | Exempt: 236 | TRF Vol: 523,033 | Short Ratio: 70.2% | Off-exchange volume (dark pool + OTC)
Mar 24, 2026
short_interest
FTD: OLMA — 78,578 shares ($1.1M) failed to deliver
Settlement: 20260324, Price: $13.97, FTD Value: $1,097,734.66, OLEMA PHARMACEUTICALS INC COM
Mar 23, 2026
short_volume
Short Volume: OLMA — 59.4% short (0.3M / 0.5M)
Short: 310,335 | Exempt: 0 | TRF Vol: 522,432 | Short Ratio: 59.4% | Off-exchange volume (dark pool + OTC)
Mar 23, 2026
short_interest
FTD: OLMA — 93,979 shares ($1.3M) failed to deliver
Settlement: 20260323, Price: $14.08, FTD Value: $1,323,224.32, OLEMA PHARMACEUTICALS INC COM
Mar 17, 2026
routine
Olema Oncology to Present Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting
Olema Oncology to Present Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting
Mar 16, 2026
earnings
Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results